-+ 0.00%
-+ 0.00%
-+ 0.00%

Kazia Therapeutics in-licenses SETDB1 platform from QIMR Berghofer for $1.39 million upfront

PUBT·04/13/2026 21:06:26
Listen to the news
Kazia Therapeutics in-licenses SETDB1 platform from QIMR Berghofer for $1.39 million upfront
  • Kazia Therapeutics in-licensed global rights to first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer.
  • Agreement includes lead candidate MSETC, an AI-discovered bicyclic peptide designed to target a disease-associated nuclear SETDB1 complex.
  • Financial terms include upfront payment of approximately USD 1.39 million.
  • Deal adds tiered revenue-sharing tied to development progress, with no clinical or regulatory milestone obligations.
  • Program remains in preclinical development with defined path toward IND-enabling studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kazia Therapeutics Limited published the original content used to generate this news brief via PR Newswire (Ref. ID: 202604131705PR_NEWS_USPR_____CN33238) on April 13, 2026, and is solely responsible for the information contained therein.